Navigation Links
SCOLR Pharma, Inc. Retains Nicholas Hall & Company

BOTHELL, Wash., Feb. 25, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC Bulletin Board: SCLR) today announced that it has retained Nicholas Hall & Company, a company providing complete support services to the global consumer healthcare industry, to introduce SCOLR to pharmaceutical companies, distributors and retailers that are interested in utilizing the Company's proprietary technology to develop OTC or prescription pharmaceutical or nutritional products.  

With more than 35 years' experience of strategic planning, market analysis and product placement, Nicholas Hall & Company, (, possesses detailed knowledge of the consumer healthcare market worldwide.  

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "Nicholas Hall & Company has a long and successful track record of assisting specialty pharma companies with their partnering and marketing strategy.  We believe their deep relationship with many of the world's leading pharmaceutical and over-the-counter (OTC) consumer products companies will be very valuable to SCOLR as we seek to partner and expand the utilization of our technology in OTC and prescription products."

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter, and nutritional products. SCOLR's CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit

Forward looking statements:

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the anticipated value of services to be provided by Nicholas Hall & Company, and the possibility of transactions involving the use of SCOLR's proprietary technology.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that SCOLR expects, believes or  anticipates will or may occur in the future.  A number of factors could  cause actual results to differ from those indicated in the forward-looking statements, including the willingness of such of third parties to partner with SCOLR on acceptable terms, or at all, competition from larger and better funded pharmaceutical companies, SCOLR's ability to manage its liquidity and obtain financing necessary to continue its operations and, global economic conditions. Additional assumptions, risks and uncertainties related to SCOLR's business are described in detail in its registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in its Annual Report on Form 10-K, as supplemented by its quarterly reports on Form 10-Q.  Such filings are available on SCOLR's website or at You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements.  SCOLR undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.  

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
2. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
3. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
4. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
5. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
7. SCOLR Pharma, Inc. Licenses Dietary Supplements
8. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
9. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
10. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):